144 ·Filed Jun 4, 2026

XERS

Xeris Biopharma Holdings, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago SEC0001950047-26-005664
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine director diversification sale following RSU vesting. The dollar amount is negligible relative to market cap. No actionable signal for traders — monitor for any follow-on insider selling patterns in future Form 4 filings.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
XERS ▲ +36.57% at T+60d
NEUTRAL call ✓ call won +36.57% · α vs SPY +32.57% · entry $6.18 → $8.44
Entry anchored
Jun 4, 2026
via day open
T+1d
+0.97%
call +0.97% · α +0.74%
$6.24
settled 4mo ago
T+5d
+9.87%
call +9.87% · α +9.30%
$6.79
settled 4mo ago
T+20d
+35.44%
call +35.44% · α +33.58%
$8.37
settled 3mo ago
T+60d
+36.57%
call +36.57% · α +32.57%
$8.44
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Director Dawn Halkuff filed a Form 144 notice of intent to sell 20,000 shares of Xeris Biopharma common stock, with an estimated aggregate market value of $117,800. The shares were acquired via restricted stock unit vesting on June 3, 2026. This is a relatively small proposed sale relative to the company's $1.0B market cap and represents a routine diversification move by a director, not a material signal of insider concern.

Key Facts

  • Director Dawn Halkuff filed Form 144 to sell 20,000 shares of XERS common stock.
  • Estimated aggregate market value of the proposed sale is $117,800.
  • Shares were acquired via restricted stock unit vesting on June 3, 2026.
  • The sale represents approximately 0.012% of the company's $1.0B market cap.
  • The filing is an advance notice of intent to sell; the sale may not be executed.

Financial Impact

Proposed sale of $117,800 in XERS common stock by a director — immaterial relative to $1.0B market cap.

dilution

Risk Factors

  • If the sale is executed, it could be followed by additional insider sales, though the current amount is too small to be concerning.
  • No other material risks identified from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005664
Document: 0001950047-26-005664-index.html0001950047-26-005664
Document: 0001950047-26-005664.txt0001950047-26-005664
14 reports for XERS
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+60▲ +24.89%Jun 12, 2026
Filters
Rows
Reports for XERS — sortable, filterable
TypeNow
Sep 9, 2026
23d ago
8-K
BULLISH ★ 6/10
$7.71 $7.78▲ +0.91%▲ +1.56%$9.08 (+17.77%)
Sep 1, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$8.58 $7.67▼ −10.61%▼ −9.65%$9.08 (+5.83%)
Aug 6, 2026
8w ago
8-K
BULLISH ★ 7/10
$7.36 $8.33▲ +13.18%▲ +11.97%$9.08 (+23.37%)
Aug 4, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$8.19 $8.39▲ +2.44%▲ +2.54%$9.08 (+10.87%)
Jul 7, 2026
12w ago
Insider Cluster
BEARISH ★ 4/10
$8.94 $8.28▲ +7.38%▲ +7.93%$9.08 (−1.57%)
Jul 2, 2026
13w ago
3
NEUTRAL ★ 3/10
$8.28 $8.62▲ +4.11%▲ +3.18%$9.08 (+9.66%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 4/10
$8.28 $8.62▲ +4.11%▲ +3.18%$9.08 (+9.66%)
Jun 30, 2026
13w ago
8-K
NEUTRAL ★ 2/10
$8.00 $8.94▲ +11.75%▲ +11.49%$9.08 (+13.50%)
Jun 12, 2026
16w ago
Institutional Cluster
BULLISH ★ 4/10
$6.79 $6.95▲ +2.36%▲ +1.68%$9.08 (+33.73%)
Jun 5, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$6.24 $6.88▲ +10.26%▲ +8.14%$9.08 (+45.51%)
Showing 10 of 14

US Market Status

Market Closed — Opens Mon (64h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access